Singer’s Elliott Management Buys Sky Stake Ahead of Vote (Bloomberg) Elliott Management Corp., the hedge fund founded by billionaire Paul Singer...
Keep Reading →
January 29 - Hedge Funds, Insider Trading - Comments
What are the best healthcare stocks to invest in? Baupost Group was founded in 1982 by Harvard Professor William Poorvu and partners Howard Stevenson,...
Keep Reading →
December 15 - Hedge Funds, News - Comments
Hedge fund managers like David Einhorn, Dan Loeb, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking...
Keep Reading →
December 11 - Hedge Funds, News - Comments
The fourth quarter of this year is set to be a big one in the biotech space, with a number of key development slated across October, November and December...
Keep Reading →
October 20 - News, Stock Analysis - Comments
U.S. stocks are mixed on Monday trading, as a spike in tech stocks countered the tumble in energy, driven by declining oil prices. Among the stocks registering...
Keep Reading →
August 1 - Earnings Report, News - Comments
Even though oil continues to plummet, the market is rebounding on Tuesday, with all major U.S stock indexes trading up. Among the stocks driving said...
Keep Reading →
March 29 - Market Movers, News - Comments
A high majority of hedge fund managers delivered a terrible performance in 2015 and widely-known value investor Seth Klarman was no exception. Baupost...
Keep Reading →
February 15 - Hedge Fund Analysis, Hedge Funds, News - Comments
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Micron and Anadarko Petroleum, have not done well during...
Keep Reading →
December 5 - Hedge Funds, News - Comments
On a day when Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is deep in the red following the release of its third quarter earnings, four other biotech stocks...
Keep Reading →
October 19 - Market Movers, News - Comments
Key bank earnings and economic data have reinvigorated the U.S stock market today. The Consumer Price Index and initial jobless claims data were better...
Keep Reading →
October 15 - Market Movers, News - Comments
Some investors think billionaire Seth Klarman is the next Warren Buffett. Given that Klarman’s $31 billion fund, Baupost Group, has achieved...
Keep Reading →
October 14 - News - Comments
Amid a broader market sell-off, several biotechnology stocks have surged in today’s trading session, although the industry overall has declined with...
Keep Reading →
September 24 - Hedge Funds, Market Movers, News - Comments
The Baupost Group is a Boston-based hedge fund founded and operated by billionaire Seth Klarman. Klarman’s fund is one of the biggest and most successful...
Keep Reading →
May 22 - Hedge Funds, News - Comments
Billionaire Seth Klarman is a notorious investor who despite his uncoventional approaches always managed to achieve high returns. He founded Baupost Group...
Keep Reading →
March 15 - Hedge Funds, News - Comments
Seth Klarman is bullish on Keryx Biopharmaceuticals (NASDAQ:KERX) and his fund, Baupost Group, has recently surged its position in the company. As a...
Keep Reading →
October 10 - Hedge Funds, News - Comments
On Wednesday, May 14th, Seth Klarman’s Baupost Group, presented its Form 13F Filing for the first quarter of 2014 at the U.S. Securities and Exchange...
Keep Reading →
May 15 - Hedge Funds - Comments
What’s a smart Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) investor to do? In the 21st century investor’s toolkit, there are dozens of indicators...
Keep Reading →
September 17 - News - Comments
Think of The Motley Fool as kind of your TiVo for investment conferences. We’ll help you skip to the good parts and zip past all the rest. There...
Keep Reading →
September 15 - News - Comments
To the average investor, there are tons of methods market participants can use to track publicly traded companies. Two of the most useful are hedge fund...
Keep Reading →
September 13 - News - Comments
Is it smart to be bullish on Neurocrine Biosciences, Inc. (NASDAQ:NBIX)? In the financial world, there are dozens of indicators investors can use to...
Keep Reading →
September 4 - News - Comments
Drugs fail their clinical trials for all kinds of reasons. Sometimes, it’s related to efficacy; sometimes, it’s safety related. Most of the...
Keep Reading →
August 30 - News - Comments
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) a good investment? In the eyes of many investors, hedge funds are seen as useless, outdated investment tools...
Keep Reading →
August 30 - News - Comments
Keryx Biopharmaceuticals (NASDAQ:KERX) announced its second-quarter results before the market opened on Thursday. Shares fell slightly as investors reacted...
Keep Reading →
August 1 - News - Comments
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a...
Keep Reading →
July 29 - News - Comments
Large healthcare companies are facing revenue declines due to expiring patents. These cash rich giants are increasingly investing in small biotechnology...
Keep Reading →
July 25 - News - Comments
The U.S. is the largest market of biotechnology products in the world. There are more than 1,300 companies involved in the research and development of...
Keep Reading →
July 18 - News - Comments
Only a handful of stocks have gained 200% in 2013, and five of those stocks are in the biotechnology industry. Perhaps you already own one, or maybe...
Keep Reading →
July 12 - News - Comments
Is Endocyte, Inc. (NASDAQ:ECYT) a marvelous investment today? The best stock pickers are in a bullish mood. The number of long hedge fund positions inched...
Keep Reading →
June 17 - News - Comments
Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) was in 10 hedge funds’ portfolio at the end of March. KYTH investors should be aware of an increase...
Keep Reading →
June 14 - News - Comments
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) was in 16 hedge funds’ portfolio at the end of March. ASTX investors should be aware of an increase in...
Keep Reading →
June 12 - News - Comments
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was in 16 hedge funds’ portfolio at the end of the first quarter of 2013. NBIX has experienced an increase...
Keep Reading →
June 6 - News - Comments
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) investors should pay attention to an increase in hedge fund interest in recent months. According to most shareholders...
Keep Reading →
June 4 - News - Comments
Keryx Biopharmaceuticals (NASDAQ:KERX) investors should pay attention to an increase in enthusiasm from smart money in recent months. In today’s marketplace...
Keep Reading →
June 3 - News - Comments
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a...
Keep Reading →
May 31 - Hedge Funds - Comments
Huge fortunes are won and lost in the world of biotech nearly every week. For those new to this world, it can appear both alluring and scary. Biotech...
Keep Reading →
May 22 - News - Comments
Editor’s Note: Related tickers: Caterpillar Inc. (NYSE:CAT), Microsoft Corporation (NASDAQ:MSFT), Keryx Biopharmaceuticals (NASDAQ:KERX), Halliburton...
Keep Reading →
April 22 - News - Comments
Keryx Biopharmaceuticals (NASDAQ:KERX) was in 6 hedge funds’ portfolio at the end of December. KERX investors should pay attention to a decrease...
Keep Reading →
April 18 - News - Comments
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you’d like to add some biotech and genome-focused...
Keep Reading →
April 16 - News - Comments
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) a safe stock to buy now? Prominent investors are in a bearish mood. The number of long hedge fund bets dropped...
Keep Reading →
April 4 - News - Comments
They don’t have any products on the market. They have little or no revenue. Earnings? Nada. Many people are betting that they will fail. And yet...
Keep Reading →
April 4 - News - Comments
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a bright light...
Keep Reading →
April 1 - News - Comments
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a...
Keep Reading →
March 20 - Hedge Funds - Comments
Young, upstart pharmaceutical and biotech companies do one thing that almost no other industry does. They go years without generating any revenue. Thanks...
Keep Reading →
March 5 - News - Comments
Recently, Keryx Biopharmaceuticals (NASDAQ:KERX) achieved a new milestone as the company declared remarkable results from its Phase 3 trials of Zerenex...
Keep Reading →
February 25 - News - Comments
Clinical trial 101 says if a trial passes all of its primary endpoints it’s successful. If it doesn’t, it’s not. With some exceptions...
Keep Reading →
February 14 - News - Comments
Keryx Biopharmaceuticals (NASDAQ:KERX)’s latest kidney drug called Zerenex is a game changer for the company after achieving positive results from its...
Keep Reading →
February 11 - News - Comments
Baltimore won. Beyonce rocked. But some health-care stocks didn’t have such great experiences. Here are three of the most horrendous performers...
Keep Reading →
February 9 - News - Comments
The market had two ways to view Friday’s employment numbers. They could go with the “glass half full” and say the private sector added...
Keep Reading →
February 5 - News - Comments
Young, upstart pharmaceutical and biotech companies do one thing that almost no other industry does. They go years without generating any revenue. Thanks...
Keep Reading →
February 2 - News - Comments
